In vitro susceptibility of oral Candida to seven antifungal agents

Oral Microbiology and Immunology

Volumn 20, Issue 6, 2005, Pages 349-353

  Kuriyama, T ^a   Williams, David W ^a   Bagg, J ^b   Coulter, W A ^c   Ready, D ^d   Lewis, M A O ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antifungal agent; Antifungal susceptibility; Candida; in vitro activity; Oral disease

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DILUTION; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; HOSPITAL DEPARTMENT; HUMAN; IN VITRO STUDY; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT; PRACTICE GUIDELINE; SPECIES; UNITED KINGDOM;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MOUTH DISEASES; NYSTATIN; PYRIMIDINES; TRIAZOLES;

EID: 27644521905     PISSN: 09020055     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-302X.2005.00236.x     Document Type: Article

References (21)

1. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002: 46: 2477-2481.
2. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002: 44: 169-174.
3. Cannon RD, Holmes AR, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995: 74: 1152-1161.
4. Davey KG, Holmes AD, Johnson EM, Szekely A, Wamock DW. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998: 36: 926-930.
5. Ellepola AN, Samaranayake LP. Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis. Dent Update 2000: 27: 165-170.
6. Espinel-Ingroff A, White T, Pfaller MA. Antifungal agents and susceptibility test. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology, 7th edn. Washington, DC: ASM Press, 1999: 1640-1662.
7. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Antimicrob Agents Chemother 2000: 44: 1585-1587.
8. Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996: 10: 263-268.
9. Krogh P, Holmstrup P, Thorn JJ, Vedtofte P, Pindborg JJ. Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol 1987: 63: 48-54.
10. Kronvall G, Karlsson I. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation. J Clin Microbiol 2001: 39: 1422-1428.
11. Kuriyama T, Williams DW, Lewis MAO. In vitro secreted aspartyl proteinase activity of Candida albicans isolated from oral diseases and healthy oral cavities. Oral Microbiol Immunol 2003: 18: 405-407.
12. Kurnatowska AJ. Search for correlation between symptoms and signs of changes in the oral mucosa and presence of fungi. Mycoses 2001: 44: 379-382.
13. Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000: 46: 338-340.
14. Munoz P, Fernandez-Turegano CP, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Frequency and clinical significance of bloodstream infections caused by C albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis 2002: 44: 163-167.
15. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard. Document M27-A, 2nd edn. Wayne: NCCLS, 2002.
16. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003: 41: 1440-1446.
17. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994: 18: 240-242.
18. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109, 496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997: 41: 575-577.
19. Samaranayake LP, MacFarlane TW, Lamey PJ, Ferguson MM. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol 1986: 15: 386-388.
20. Stevens DA, Stevens JA. Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 1996: 26: 145-148.
21. Waltimo TM, Ørstavik D, Meurman JH, Samaranayake LP, Haapasalo MP. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol 2000: 15: 245-248.